Literature DB >> 6110381

Future nursing homes in Sweden -- users' opinion.

T Svensson, G Hultén.   

Abstract

The purpose of this study was to gather knowledge in order to provide a basis for the future planning of local nursing homes in Sweden. A total of 306 patients, residents and staff of six nursing homes and four old age homes were interviewed. The interview was combined with questions regarding a model for the design of a nursing home. The subjects were found to have opinions on the designs on the design which, in some cases, differed significantly from what is generally assumed to be true today in Sweden.

Entities:  

Mesh：

Year:  1980        PMID： 6110381

Source DB:  PubMed          Journal:  Aktuelle Gerontol        ISSN： 0300-5704


  3 in total

1.  Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy.

Authors:  Dongli Cai; Jiaming Li; Dingfeng Liu; Shanjuan Hong; Qin Qiao; Qinli Sun; Pingping Li; Nanan Lyu; Tiantian Sun; Shan Xie; Li Guo; Ling Ni; Liping Jin; Chen Dong
Journal:  Cell Mol Immunol       Date:  2019-10-14       Impact factor: 11.530

2.  The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.

Authors:  Shogo Kumagai; Yosuke Togashi; Takahiro Kamada; Eri Sugiyama; Hitomi Nishinakamura; Yoshiko Takeuchi; Kochin Vitaly; Kota Itahashi; Yuka Maeda; Shigeyuki Matsui; Takuma Shibahara; Yasuho Yamashita; Takuma Irie; Ayaka Tsuge; Shota Fukuoka; Akihito Kawazoe; Hibiki Udagawa; Keisuke Kirita; Keiju Aokage; Genichiro Ishii; Takeshi Kuwata; Kenta Nakama; Masahito Kawazu; Toshihide Ueno; Naoya Yamazaki; Koichi Goto; Masahiro Tsuboi; Hiroyuki Mano; Toshihiko Doi; Kohei Shitara; Hiroyoshi Nishikawa
Journal:  Nat Immunol       Date:  2020-08-31       Impact factor: 25.606

Review 3.  Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.

Authors:  Michael J Grant; Roy S Herbst; Sarah B Goldberg
Journal:  Nat Rev Clin Oncol       Date:  2021-06-24       Impact factor: 66.675
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.